MotzerRAlekseevBRhaS-Y, et al.
Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med2021;
384: 1289–1300.
2.
KhalilNSarkisJAbi TayehG.Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 in renal cell carcinoma: lessons from CheckMate 9ER and IMmotion 151. J Oncol Pharm Pract2021;
27: 266–267.
3.
LaraPNJrandPalSK.The trouble with doublets: making sense of combination strategies in advanced kidney cancer. KCA2020;
4: 167–168.
4.
Parikh, Divya & Serrato, Paul & Srinivas, Sandy & Ryckman, Tess & Salomon, Joshua & Goldhaber-Fiebert, Jeremy. (2020). Cost-effectiveness of first-line therapy for advanced renal cell carcinoma in the immunotherapy era.. Journal of Clinical Oncology. 38. e19392–e19392. 10.1200/JCO.2020.38.15_suppl.e19392.
5.
WatsonTRGaoXReynoldsKL, et al.
Cost-effectiveness of pembrolizumab plus axitinib vs nivolumab plus ipilimumab as first-line treatment of advanced renal cell carcinoma in the US. JAMA Netw Open2020;
3: e2016144.
6.
PrzybylskiDJBergsbakenJJPiccoloJK.Unleashing the power of immunotherapy and targeted therapy combinations: advancing cancer care or discovering unknown toxicities?J Oncol Pharm Pract2021;
27: 930–938.
7.
RiniBIPlimackERStusV, et al.
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med2019;
380: 1116–1127.
8.
ChoueiriTKPowlesTBurottoM, et al.
696O_PR nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. Ann Oncol2020;
31: S1159.
9.
SarkisJAssafJAlkassisM.Biomarkers in renal cell carcinoma: towards a more selective immune checkpoint inhibition. Transl Oncol2021;
14: 101071.
10.
Maia MC, Bergerot PG, Dizman N, Hsu J, Jones J, Lanman RB, Banks KC, Pal SK. Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden. Kidney Cancer. 2017 Jul 26;1(1):65-70. doi: 10.3233/KCA-170007. PMID: 30334006; PMCID: PMC6179113.
11.
Deprimo SE, Bello CL, Smeraglia J, Baum CM, Spinella D, Rini BI, Michaelson MD, Motzer RJ. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007 Jul 2;5:32. doi: 10.1186/1479-5876-5-32. PMID: 17605814; PMCID: PMC1939830.
12.
MitchellTCHamidOSmithDC, et al.
Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase I/II trial (ECHO-202/KEYNOTE-037). J Clin Oncol2018;
36: 3223–3230.
13.
LeoneRDEmensLA.Targeting adenosine for cancer immunotherapy. J Immunother Cancer2018;
6: 57.
14.
Choueiri TK, Plimack ER, Bauer TM, Merchan JR, Papadopoulos KP, McDermott DF, et al. Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). J Clin Oncol. 2020 Feb 20;38(6_suppl):611–611.
15.
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan V, Maughan BL, et al. Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma. J Clin Oncol. 2020 May 20;38(15_suppl):5003–5003.
16.
Merck Sharp & Dohme Corp. An open-label, randomized phase 3 study of MK-6482 versus everolimus in participants with advanced renal cell carcinoma that has progressed after prior PD-1/L1 and VEGF-targeted therapies. Report no.: NCT04195750, https://clinicaltrials.gov/ct2/show/NCT04195750 (accessed 14 March 2021).
